Best Life Sciences Companies in Norway
The 186 best Life Sciences companies in Norway in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Calluna Pharma.
Norway's Life Sciences sector draws more capital than most people expect for a market this size. Our directory tracks 186 companies with $624M in total disclosed funding, and the range tells you everything: Calluna Pharma leads at $82M, CardioMech has pulled $42M, and Cytovation sits at $32M, meaning the top three alone account for well over a quarter of the pool. No unicorns yet, but the funding distribution is tightening around a core of serious clinical-stage bets. Investors like Investinor, Sarsia Seed, and the EIC Fund keep returning, which signals conviction rather than opportunism.
So what's pulling the money in? The global life sciences market was valued around $167.8B with a CAGR of roughly 10.2%, and an aging population is only accelerating that demand curve. I'd also point you to the digital side: median install growth across life and health sciences apps is running at roughly +43% YoY across 15 tracked categories, a sign that distribution and patient-facing tooling are becoming real commercial layers. Norway's regulatory environment rewards methodical development, which fits the profile of what you see here: companies building for durability, not just for the next round.
- Morgan Stanley Ups the Ante on These 2 Life Science Tool Stocks
Our analysis of 576 Life Sciences companies
$91.7b in tracked funding; 70% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences companies in Norway
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Web popularity | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Calluna Pharma Developer of therapeutics for inflammatory and fibrotic diseases | $82M | 28 mo ago | — | Jonas Hallen Founder | — | — | — | — |
| 2 | BerGenBio Developer of therapeutics for cancer and severe respiratory infections | $74M | 73 mo ago | 45 | — | Apple iCloud MailMicrosoft 365Node.js+16 | Top 50M | 52 patents AXL kinase inhibition and antibody therapeutics for cancer treatment | — |
| 3 | Nordic Nanovector Developer of antibody radionuclide conjugates for haematological cancers | $52M | 53 mo ago | 40 40 → 24 (-40%) · sector median -16% | — | — | — | 98 patents Radioimmunoconjugate antibodies targeting CD37 for lymphoma therapy | 1 job opening |
| 4 | Hofseth BioCare Manufacturer of salmon oils, calcium bone powder and salmon protein hydrolysate | $47M | 47 mo ago | 63 63 → 53 (-16%) · sector median -16% | — | Craft CMSPHPYii+18 | Top 10M | 71 patents Omega-3 rich fish oil and protein hydrolysate therapeutics for respiratory inflammation | — |
| 5 | CardioMech Developing a catheter-based mitral valve repair system | $42M | 14 mo ago | 4 | Jacob Bergsland Co-Founder & CMO | — | — | 130 patents Cardiac repair devices and soft‑tissue anchoring systems for heart surgery | — |
| 6 | Ultimovacs Developer of next-generation cell therapies for solid tumors | $32M | 55 mo ago | 25 | — | — | — | 29 patents Therapeutic cancer vaccines combining telomerase antigens with immune‑checkpoint inhibitors | — |
| 7 | Cytovation Developerof peptide therapeutics to treat cutaneous warts caused by HPV | $32M | 13 mo ago | 10 | Lars Prestegarden CEO | WordPressMySQLPHP+21 | Top 50M | 31 patents Peptide-based therapeutic compositions and combination regimens for cancer treatment | 1 partnership |
| 8 | Oncoinvent Developer of radioisotope-based anti-cancer therapeutics | $31M | 73 mo ago | 27 27 → 50 (+85%) · sector median -16% | — | WordPressMySQLPHP+17 | Top 10M | 43 patents Targeted alpha‑emitting radiopharmaceuticals and antibody‑based cancer therapeutics | — |
| 9 | Arctic Bioscience Developer of the drug for psoriasis | $30M | 64 mo ago | 13 | Christer Valderhaug CEO | WordPressWordPress Block EditorMySQL+14 | Top 10M | — | 1 launch · 1 partnership · 1 expansion |
| 10 | Algeta Developing alpha particle-emitting pharmaceutical with an anti-tumor effect for the treatment of cancer. | $29M | 249 mo ago | 175 | — | — | — | 56 patents Targeted alpha‑emitting radiopharmaceuticals (Thorium‑227) for soft‑tissue and bone cancer therapy | — |
| 11 | Lytix Biopharma Developer of oncolytic peptide immunotherapy for solid tumors | $20M | 18 mo ago | 7 | — | — | — | 162 patents Peptide-based oncolytic and immunotherapy formulations using chitosan delivery systems | — |
| 12 | EXACT Therapeutics Provider of sonoporation platform for diagnosis of multiple diseases | $16M | 71 mo ago | 7 | Masha Stromme CEO | Cart FunctionalitySquarespace CommerceSquarespace+11 | Top 50M | 48 patents Ultrasound-based drug delivery and ablation technologies with dose calculation software. | — |
| 13 | ConCordix Manufacturer of vitamin and supplements for the nutraceutical and dietary supplement industry | $15M | 191 mo ago | — | Klaus Neumann Chief Executive Officer | WordPressMySQLPHP+20 | Top 10M | — | — |
| 14 | Arxx Therapeutics Developer of monoclonal antibody for fibrotic disease | $13M | 63 mo ago | 2 | Jonas Hallen Co-Founder | — | — | 13 patents Humanized therapeutic antibodies targeting S100A4 for fibrosis and systemic sclerosis treatment | — |
| 15 | SantoSolve Develops targeted pain therapeutics | $12M | 198 mo ago | 8 | — | — | — | 25 patents Strontium-based anti‑inflammatory and analgesic formulations for topical soft‑tissue pain relief | — |
| 16 | Iris.Ai Developer of an AI platform for enterprise research and development | $9M | 24 mo ago | 23 | Jacobo Elosua Co-Founder & CMO | SentryTypeScriptTailwind CSS+20 | Top 5M | — | 1 partnership |
| 17 | Zelluna Immunotherapy Developer of TCR-based therapies for a wide range of cancer types | $8M | 45 mo ago | 18 18 → 23 (+28%) · sector median -16% | — | WordPress Block EditorWordPressMySQL+19 | Top 10M | 5 patents Engineered NK cell therapies and MAGE‑A4 specific TCR‑modified T cell immunotherapies | 1 job opening |
| 18 | OncoImmunity Developer of machine-learning based software for personalized cancer immunotherapy | $7M | 55 mo ago | 16 | Richard Stratford Co-founder and Advisor | — | — | 4 patents Predictive peptide selection for MHC presentation in cancer immunotherapy and vaccine design | 1 job opening |
| 19 | CIMON Medical Developer of a patented device for monitoring blood flow for early diagnosis | $7M | 66 mo ago | 5 | — | — | — | 17 patents Ultrasound probe attachment devices enabling real-time blood‑flow monitoring in medical imaging | — |
| 20 | Glucoset Indwelling intravascular continuous blood glucose monitoring device | $7M | 35 mo ago | 19 19 → 16 (-16%) · sector median -16% | — | Squarespace CommerceSquarespaceVimeo+12 | Top 50M | 3 patents Boronic‑acid polymer glucose sensors integrated with optical‑fiber detection. | — |
| 21 | Targovax Vaccine and adenovirus-based immunotherapy to treat different cancer such as pancreatic, mesothelioma… | $6M | 156 mo ago | 23 | — | — | — | 8 patents Peptide-based cancer immunotherapies, especially mutant RAS peptide vaccines combined with chemotherapeutics. | — |
| 22 | CellCura Cell Culture reagent provider | $4M | 148 mo ago | — | Pål Bråthen CEO | — | — | 2 patents Automated sperm analysis and imaging diagnostics for reproductive health | — |
| 23 | Biovotec Developing biological wound dressing based on the hen eggshell membrane | $4M | 80 mo ago | 5 | Henri-Pierre Suso Co founder and CTO at Biovotec | — | — | 45 patents Eggshell membrane-derived biomaterials for wound healing and peptide delivery systems. | — |
| 24 | APIM Therapeutics Developer of anti-cancer therapies potentiating chemotherapy induced responses in cancer cells | $4M | 61 mo ago | 1 | — | — | — | 37 patents Peptide therapeutics targeting PCNA-mediated protein interactions for cancer treatment | — |
| 25 | Clavis Pharma Developer of novel small molecule therapeutics for cancer | $3M | 173 mo ago | — | Carlos Roig Founder | — | — | 84 patents Antibody therapeutics targeting ENT1 and prodrug formulations of nucleoside analogs and glucocorticoid esters for cancer and infla | — |
| 26 | EpiGuard Developer of medical isolation and transportation systems | $3M | 55 mo ago | 17 | Fridtjof Heyerdahl Founder & CMO | WordPressMySQLPHP+25 | Top 50M | 4 patents Secure patient transport systems and isolation devices for medical transport | — |
| 27 | Vectron Biosolutions Provider of expression technology and services | $3M | 60 mo ago | 7 | — | WebflowAmazon Web Servicescore-js+10 | Top 50M | 12 patents Design of synthetic mRNA leader sequences to boost recombinant protein expression | — |
| 28 | Sensocure Provider of a biosensor based medical devices for the treatment of ischemia | $3M | 41 mo ago | 19 19 → 23 (+21%) · sector median -16% | — | — | — | 30 patents Patents concentrated in health & consumer products | — |
| 29 | SoftOx Developer of topical antiseptic products for chronic wounds | $2M | 44 mo ago | 21 21 → 13 (-38%) · sector median -16% | Geir Hermod Almas CEO | WordPressMySQLPHP+31 | Top 10M | 11 patents Formulating and dispensing hypochlorous‑acid based disinfectants and biofilm treatments. | — |
| 30 | OstomySecure Developer of a transcutaneous implant evacuation system for ileostomy patients | $2M | 89 mo ago | — | Bente Buverud Founder | WordPressMySQLPHP+22 | Top 10M | — | — |
| 31 | AlgiPharma Developer of pharmaceutical technologies | $2M | 101 mo ago | — | Yngvar Berg CEO | — | — | 172 patents Alginate oligomer drug delivery systems for oral/inhaled bioavailability, antimicrobial and anticoagulant therapies | — |
| 32 | Augere Medical Provider of AI-based cancer detection device | $2M | 19 mo ago | 4 | — | WordPressMySQLPHP+11 | Top 10M | 6 patents Real-time video object detection algorithms for medical imaging and diagnostics | — |
| 33 | Nisonic Developer of device for detecting intracranial pressure | $2M | 95 mo ago | 2 | — | — | — | 10 patents Ultrasound image alignment and non‑invasive optic nerve sheath pulsatility monitoring for ocular diagnostics | — |
| 34 | Lyfstone Provider of diagnostic test and biomarkers for orthopedics | $2M | 219 mo ago | 12 | Stein Lian CEO | — | — | 8 patents Diagnostic biomarkers and kits for predicting aseptic loosening risk in orthopedic implants | — |
| 35 | Pre Diagnostics Blood based diagnostics for Alzheimer's disease. | $2M | 54 mo ago | 8 | — | — | — | — | 1 partnership |
| 36 | Pharmasum Therapeutics Kinase inhibitor for Alzheimer's disease | $2M | 136 mo ago | — | Anders Fugelli Co-Founder & CEO | — | — | 7 patents Small-molecule benzothiazole DYRK1 kinase inhibitors for therapeutic applications | — |
| 37 | Resani Developer of hand sanitizing technology for hospitals | $1M | 37 mo ago | 3 | — | — | — | 5 patents Hand hygiene devices and methods for personal sanitization | — |
| 38 | Bio-Me Developer of a platform for gut microbiome analysis | $1M | 42 mo ago | 12 | Morten Isaksen CEO | WordPressMySQLPHP+33 | Top 50M | — | 2 partnerships |
| 39 | ClexBio Developer of microfluidic chip for laboratory purposes | $1M | 18 mo ago | 4 | Armend Hati Co-Founder & CEO | — | — | — | — |
| 40 | Nykode Therapeutics Developer of vaccines and immunotherapeutics for cancer and infectious diseases | $961K | 135 mo ago | 102 102 → 73 (-28%) · sector median -16% | Agnete Fredriksen Co-Founder & Chief Business Officer | WordPressApple iCloud MailMicrosoft 365+23 | Top 10M | 110 patents Protein-based immunogenic constructs and neoepitope vaccines for cancer and infectious disease therapy | — |
| 41 | Circio Developer of immunotherapies for cancer treatment | $956K | 18 mo ago | 17 | Erik Digman Wiklund Chief Executive Officer | WordPressMySQLPHP+19 | Top 5M | — | 1 partnership |
| 42 | Cardinor Provider of biomarker-based assays for cardiovascular diseases | $922K | 62 mo ago | 2 | — | — | — | 2 patents Immunoassay techniques for measuring secretoneurin peptide levels | — |
| 43 | HBC Immunology Developer of peptide-based therapeutics for solid tumors | $900K | 34 mo ago | — | Bomi Framroze CEO | — | — | — | — |
| 44 | Age Labs Developer of molecular diagnostic solutions for the detection of age-related diseases | $876K | 74 mo ago | 4 | Karl Trygve Kalleberg Co-Founder & CTO | WebflowreCAPTCHAHSTS+4 | Top 50M | 5 patents Diagnostic screening assays for rheumatoid arthritis and severe COVID-19 susceptibility biomarkers | — |
| 45 | Lifecare Provider of invasive app-based smart sensor for glucose monitoring | $774K | 56 mo ago | 2 | Rune Frisvold CEO - COO 2012 - 2021 | WordPressMySQLPHP+11 | Top 10M | 44 patents Measuring interstitial fluid osmotic pressure and related fluid composition formulations. | — |
| 46 | Akvaforsk Genetics Provider of technical genetic improvement services to aquaculture industries | $530K | 89 mo ago | — | Morten Rye CEO & MD | — | — | — | — |
| 47 | Hy5 Hydraulic prosthesis for amputees | $514K | 66 mo ago | — | Christian Stray Co-Founder & CEO | — | — | — | — |
| 48 | Spiro Medical Developer of smart ApneaGraph devices for sleep monitoring | $500K | 32 mo ago | — | Magne Tvinnereim CEO | — | — | 9 patents Invasive physiological monitoring: temperature/pressure catheters and respiratory effort sensors | — |
| 49 | Bulbitech Developer of a neuro-ocular diagnostic device to use during the eye examination | $325K | 40 mo ago | 17 | Dennis Hens Chief Executive Officer | WordPressMySQLPHP+34 | Top 10M | — | — |
Top 12 Life Sciences companies in Norway
#1
Series B · Trondheim, Trondelag · founded 2015 · 4 employees$42Mraised▾
CardioMech is developing a catheter-based mitral valve repair system. It includes the implantation of an artificial chordae, using catheters through veins up to the heart.
- Apr 2025Conventional Debt$17.6M
- Dec 2023Series B$13M
- Aug 2020Series A$18.5M
- Aug 2019Series A$5M
#2
Series A · Bergen, Vestland · founded 2001 · 10 employees$31.6Mraised▾
Developer of peptide therapeutics to treat cutaneous warts caused by HPV. The company's proprietary product, CyPep-1, is a peptide consisting of 27 amino acids with a mechanism that rapidly and selectively targets tumor cells due to altered electrochemical properties on their cell membranes not found on healthy cells.
- Apr 2025Series A$6M
- Jun 2023Series A$8M
- Jan 2022Series A$20M
- Jan 2018Series A$1.2M
#3
Public · Oslo, Oslo · founded 2003 · 7 employees$20.4Mraised▾
Lytix Biopharma develops oncolytic immunotherapies. Its lead candidate is LTX-315, an oncolytic peptide is being developed to treat solid cancer (phase I/II). It is also developing LTX-315 in combination with checkpoint inhibitors to treat cancer (preclinical/phase1) and a candidate under investigation for multidrug-resistant infections.
- Dec 2024Post IPO$9M
- Oct 2023Grant (prize money)$1.3M
- Aug 2017Series A$758.6K
- Dec 2015Series A$9.2M
#4
Series A · Oslo, Oslo · founded 2024$81.7Mraised▾
Developer of therapeutics for inflammatory and fibrotic diseases. The company is developing a pipeline of antibodies targeting a comprehensive range of disease-associated with precision targeting of upstream innate immune amplifiers for inflammatory and fibrotic diseases.
- Jan 2024Series A$81.7M
#5
Seed · Oslo, Oslo · founded 2018 · 4 employees$2.1Mraised▾
Augere provides an AI-based cancer detection device. It analyses video in real-time. It can connect to any vendor's equipment. It gives the endoscopist a real-time probability of early-stage lesions.
- Nov 2024Seed$2.1M
#6
Seed · Oslo, Oslo · founded 2020 · 4 employees$1.2Mraised▾
Developer of a microfluidic chip for laboratory purposes. It uses hydrogel technology CLEX that allows hydrogel formation with, both, precise control and exceptional biocompatibility. This enables users to use microfluidic devices to form hydrogel microstructures containing delicate biological cargo such as living cells.
- Nov 2024Seed—
- Jul 2021Grant (prize money)$1M
- Jul 2021Seed$1.2M
#7
Public · Oslo, Oslo · founded 2010 · 17 employees$956.4Kraised▾
Developer of immunotherapies for cancer treatment. It offers circular RNA platform for developing medicines based on a modular genetic cassette design for expression of therapeutic proteins directly into cancer cells. It provides a lead candidate ONCOS-102 a monotherapy and in combinations with checkpoint inhibitors for melanoma, and TG01 is an immunotherapy targeting KRAS driver mutations for pancreatic cancer.
- Dec 2024Post IPO$956.4K
#8
Series A · Haslum, Viken · founded 2015 · 23 employees$8.7Mraised▾
Developer of an AI platform for enterprise research and development. The platform facilitates the connection, orchestration, evaluation, and deployment of agentic RAG AI workflows. It offers tools for building, managing, and monitoring AI systems. The platform supports data ingestion, custom evaluation frameworks, and performance monitoring. It also provides training for managing agents and crafting prompts.
- May 2024Series A$8.3M
- Jan 2023Series A$12.9M
- Jan 2023Grant (prize money)$2.6M
- Nov 2018Grant (prize money)$56.9K
#9
Public · Oslo, Oslo · founded 2009 · 40 employees$51.7Mraised▾
Developer of antibody radionuclide conjugates for hematological cancers. The company's lead product includes Betalutin, an ARC that comprises a tumor-seeking anti-CD37 antibody conjugated to a low-intensity radionuclide (Lutetium 177). It is used to treat blood cancer non-Hodgkin Lymphoma.
- Jan 2022Post IPO—
- Feb 2021Post IPO—
- Sep 2020Post IPO$24.9M
- Dec 2019Post IPO$1.3M
#10
Public · Alesund, More og Romsdal · founded 2009 · 63 employees$47.3Mraised▾
Manufacturer of salmon oils, calcium bone powder and salmon protein hydrolysate
- Jul 2022Post IPO$14.2M
- Nov 2021Post IPO$11.5M
- Oct 2020Post IPO$21.7M
#11
Acquired · Trondheim, Trondelag · founded 2013 · 19 employees$6.6Mraised▾
Indwelling intravascular continuous blood glucose monitoring device. The GlucoSet intravascular sensor delivers continuous and accurate information on patient's blood glucose level, enabling normalization of glucose levels, without the risk of sudden and dangerously low glucose levels. By accessing through an indwelling arterial catheter without disrupting that catheter's current use, the GlucoSet sensor requires no new catheters and displaces no other equipment. The company claims that unlike competing solutions, the sensor also tolerates patient movement very well. The company also claims that with a sensor cross sectional area under 5% of the smallest competing product, GlucoSet is the first sensor able to access through arterial catheters without risk.
- Jul 2023Series A$6.5M
- Jul 2023Grant (prize money)$3.7M
- Nov 2020Grant (prize money)$59.8K
- Oct 2018Grant (prize money)$2.8M
#12
Public · Bergen, Vestland · founded 2007 · 45 employees$74.1Mraised▾
Developer of therapeutics for cancer and severe respiratory infections. It is a biopharmaceutical company focused on developing epithelial-mesenchymal transition inhibitors to treat aggressive cancers. It is using its own proprietary suite of complimentary technologies CellSelect used to identify and validate novel drug targets and biomarkers. Its lead product is BGB324, an Axl kinase inhibitor is in clinical trials for patients with Acute myeloid leukemia.
- May 2020Post IPO$49.8M
- Jan 2020Post IPO$24M
- Jun 2019Series C$8.7M
- Apr 2018Post IPO$24M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Biotechnology is moving in Norway
A read on the academic research around Biotechnology — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 158 Norway-affiliated papers.
- Abilia22
- Norwegian University of Life Sciences18
- Norwegian University of Science and Technology15
- University of Oslo13
- Norwegian Veterinary Institute10
- Cell culture3
- Lignocellulosic biomass2
- Biomass (ecology)2
- Embryonic stem cell2
- Agriculture2
- Aquaculture4
- Raw material4
- Bacteria3
- Gene3
- Gut flora3
- Aquaculture6
- Fish
4 - Replication (statistics)4
- Statistical analysis4
- Antimicrobial2
Where biotechnology is researched across Norway
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.